We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Doctors Without Borders VS Johnson and Johnson Who Will Not Donate Licenses for HIV/AIDS Drugs as Others Have
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Global Healthcare > Doctors Without Borders VS Johnson and Johnson Who Will Not Donate Licenses for HIV/AIDS Drugs as Others Have
BusinessGlobal HealthcareNews

Doctors Without Borders VS Johnson and Johnson Who Will Not Donate Licenses for HIV/AIDS Drugs as Others Have

BarbaraDuck
BarbaraDuck
Share
3 Min Read
SHARE

Johnson and Johnson refuses to join the Medicines Patent Pool as others have done so generic drugs can be made in developing countries. As you can read through here, they do get some small payments from licensing the drugs and the other countries might just do a copy cat anyway.Johnson and Johnson refuses to join the Medicines Patent Pool as others have done so generic drugs can be made in developing countries. As you can read through here, they do get some small payments from licensing the drugs and the other countries might just do a copy cat anyway.image

Johnson and Johnson said there was no urgency here but that does not seem to be the case if you just read the news. In saying no to the Medicines Patent Pool, Johnson & Johnson has made a conscious, willful decision to turn its back on people living with HIV and there’s even one license held by the NIH that is useless as it is a partial patent for darunavir so without all being members not much gets done. Here’s a video from South Africa with one doctor talking about their need for some of the J and J drugs. BD

aram>mbed>bject>iv>”;” alt=””>
HIV-AIDS Drugs

At the end of 2011, there were about 15 million people who needed HIV/AIDS treatment, but only about 6 million people received proper care. Part of the reason is that it is costly to treat HIV/AIDS and most people living with HIV/AIDS are poor and live in countries that simply don’t have the means to provide treatment to everyone who needs it.

Although the cost of standard HIV/AIDS treatments have gone down significantly over the years, there are still certain specialized medicines or specialized combinations of medicines that are really expensive. One idea that humanity drew up to reduce the costs of these expensive treatments is something called the Medicines Patent Pool.

The idea is pretty basic. Patent holders from western pharmaceutical giants voluntarily give up their patents for expensive AIDS drugs. A World Health Organization-certified drug manufacturer in say, in India or Kenya, produces cheap generic versions of these expensive drugs for the exclusive sale in the developing world. They pay a royalty to the original western patent holder, but nothing too onerous.

The western pharma giant gets paid (and gains access to new markets). HIV patients in the developing world get their medicines cheap. Everyone wins, right? Not so, says Johnson & Johnson which is refusing to turn over three of its patents to the pool.

http://www.undispatch.com/doctors-without-borders-v-johnson-johnson

Technorati Tags: HIV,AIDS,Johson and Johnson,drugs,patents,generic drugs,pharma,royalties


More Read

NCQA Accreditation
Is NCQA Accreditation Right for You?
Health Care Buzz Today
Actuarial Study Results a Mixed Bag on Costs of Claims under ACA
Seeking Holy Grail: Quest for Stem Cells from Embryos Continues
It’s Time to Measure Patient Outcomes

TAGGED:AIDSHIVJohnson & Johnsonpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

How to Choose an On-Demand Medical Interpreting Provider for Your Hospital -- AI-generated illustration
How to Choose an On-Demand Medical Interpreting Provider for Your Hospital
Health care
August 12, 2026
The Chemistry Of Drug Consistency -- AI-generated illustration
The Chemistry Of Drug Consistency
Policy & Law
August 12, 2026
Dental Materials Through The Decades -- AI-generated illustration
Dental Materials Through The Decades
Dental health Infographics Specialties
August 12, 2026
DNP or PhD: What Each Actually Means for Your Nursing Career -- AI-generated illustration
DNP or PhD: What Each Actually Means for Your Nursing Career
Career Nursing
August 12, 2026

You Might also Like

Rite Aid Stores Hosts RV Tour For a Free Skin Cancer Screen

March 23, 2012

Doctor/Patient Relationship-Are the Surveys Accurate?

February 6, 2013
massachusetts general hospital
BusinessSocial Media

Who Knew? Facebook Tops HCAHPS as Measure of Care

April 9, 2015
medication heart
BusinessFinanceHospital AdministrationPolicy & Law

4 Reasons Doctors Are Taking a Fresh Look at In-Office Dispensing

January 9, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?